News
ProteLight Pharma Completes First Human Dosing of Antimicrobial Peptide PL-3301 Oral Gel in Phase I Clinical Trial

ProteLight Pharma Completes First Human Dosing of Antimicrobial Peptide PL-3301 Oral Gel in Phase I Clinical Trial

Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. ("ProteLight Pharma") announced on October 16, 2025, the completion of the first participant enrollment and dosing in the Phase I clinical trial for its first-in-class drug, Antimicrobial Peptide PL-3301 Oral Gel, with safety follow-up for the participants currently ongoing.

16

2025

/

10

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-18 Suppository Has Received FDA Approval to Commence Clinical Studies.

On October 26, 2024, Jiangsu ProteLight Pharmaceutical & Biotechnology Co., Ltd. ("ProteLight Pharma") received a Study May Proceed (SMP) letter from the FDA, indicating that the company's innovative Antimicrobial Peptide PL-18 Suppository has been approved for the Phase II clinical study in the United States.

26

2024

/

10

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

ProteLight Pharma’s Innovative Antimicrobial Peptide PL-3301 Oral Gel Has Been Granted FDA Approval To Commence Clinical Trials.

17

2024

/

06

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

The publication of a confirmative Phase III clinical study on Peceleganan Spray (project code: PL-5), an innovative antimicrobial peptide developed by ProteLight Pharms, has been released.

14

2024

/

06

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

ProteLight Pharma was selected into the list of “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”

October 2023, Healthcare Executive Magzine released the lists of “Top 100 Chinese Pharmaceutical Innovative Enterprises in 2023” and “Top 100 Chinese Pharmaceutical Innovative Seed Enterprises in 2023”.

26

2023

/

10

Congratulations to the company for passing the ISO9001 quality management system certification

Congratulations to the company for passing the ISO9001 quality management system certification

Jiangsu Protelight Pharmaceutical Biotechnology Co., Ltd. successfully passed the certification of the ISO9001 quality management system

08

2023

/

09

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China

Antimicrobial Peptide PL-18 Suppository (First-in-class new drug) of ProteLight Pharma Received Clinical Trial Approval from CDE in China

Recently, Jiangsu ProteLight pharmaceutical & Biotechnology Co., Ltd. (abbreviated as: ProteLight Pharma) announced that the Antimicrobial Peptide PL-18 Suppository with independent intellectual property rights as first-in-class new drug has received Clinical trial approval from CDE in China and passed ethical review. Now, the project will launch Phase Ⅰ clinical study in China.

01

2023

/

02

ProteLight Pharma Received the Approval for its First Human Clinical Study in Australia for the Antimicrobial Peptide PL-18 Suppository

ProteLight Pharma Received the Approval for its First Human Clinical Study in Australia for the Antimicrobial Peptide PL-18 Suppository

ProteLight Pharma announced that its PL-18 suppository, the Chinese national category I new drug, a novel antimicrobial peptide, has passed ethical review by the Australian Therapeutic Goods Administration (TGA), and will start its first human clinical study in Australia.

25

2022

/

04

< 123456 >